Cargando…

Changes in the pharmacokinetic of sildenafil citrate in rats with Streptozotocin-induced diabetic nephropathy

AIM: The present investigates deals with the change in the pharmacokinetic of Sildenafil citrate (SIL) in disease condition like diabetic nephropathy (DN). METHOD: Diabetes was induced in rats by administering Streptozotocin i.e. STZ (60 mg/kg, IP) saline solution. Assessment of diabetes was done by...

Descripción completa

Detalles Bibliográficos
Autores principales: Tripathi, Alok S, Mazumder, Papiya M, Chandewar, Anil V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922855/
https://www.ncbi.nlm.nih.gov/pubmed/24398037
http://dx.doi.org/10.1186/2251-6581-13-8
Descripción
Sumario:AIM: The present investigates deals with the change in the pharmacokinetic of Sildenafil citrate (SIL) in disease condition like diabetic nephropathy (DN). METHOD: Diabetes was induced in rats by administering Streptozotocin i.e. STZ (60 mg/kg, IP) saline solution. Assessment of diabetes was done by GOD-POD method and conformation of DN was done by assessing the level of Creatinine, Blood Urea Nitrogen (BUN) and Albuminurea. After the conformation of DN single dose of drug SIL (2.5 mg/kg, p.o.) were given orally and Pharmacokinetic Parameters like [AUC o-t (ug.h/ml), AUC 0-∞, C(max), T(max), Kel, Clast] were estimated in the plasma by the help of HPLC-UV. RESULT: There was significant increase (p < 0.01) in the Pharmacokinetic parameters of SIL in DN rat (AUC(0-t), AUC(0-∞), C(max), T(max) and T(1/2)) compare to normal control rat and significant increase Kel in the DN rat compare to control rat. CONCLUSION: The study concluded that there was significant (p < 0.01) increase in the bioavailability of SIL in DN.